Studies (49, 50) have shown that HER2-low TNBC may inhibit antigen presentation through HLA gene hypermethylation, reducing immune cell infiltration within the tumor and forming an immune escape microenvironment. The gene discussed is ERBB2; the disease is neoplasm.